Carving Out New Spaces In Cancer Immunotherapy
An Interview With iTeos Therapeutics co-founder, president and CEO Michel Detheux
Executive Summary
With a combined $335m raised in a crossover series B funding and an IPO last summer, Cambridge, MA-based iTeos Therapeutics has the juice to move its two cancer immunotherapy clinical programs forward.
You may also be interested in...
Interview: iTeos Attracts Investors By Targeting TIGIT
The Belgian biotech has managed to attract considerable sums from venture capitalists over the past couple of years amid hopes that its two next-generation immunotherapies will be best-in-class agents.
iTeos Says Adios To IDO And Eyes US IPO
An oversubscribed financing round led by new US investor MPM Capital has brought in $75m for the Belgian company. Much of it will be used to advance its potential best-in-class adenosine A2A receptor now that its IDO1 drug has been shelved.
Microsoft’s Strategy In Health Care: Connection, Not Disruption
Through an ever-growing number of partnerships, grants and investments in the health care sector, Microsoft is taking a lead from behind approach to improve and expand interoperability, increase data security and analytics, and provide partners with tools, technology, and a platform for growth.